The US Food and Drug Administration (FDA) has granted fast track designation for the development of Bracco Imaging's molecular imaging ultrasound contrast agent, BR55, to identify active bowel ...
The company is currently preparing for Phase III trials to further assess the efficacy and safety of the agent in identifying active inflammation in individuals with Crohn's disease. Credit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback